Clik here to view.
Hoya Reports First Quarter Financial Results
TOKYO HOYA Corporation (TOKYO:7741) today announced financial results for the first quarter ended June 30, 2017. During the quarter, revenues increased 10.4% year on year, reaching 127,158 million...
View ArticleClik here to view.
CHMP对杨森公司治疗HIV的首个含Darunavir的单一片剂方案SYMTUZA™签发肯定意见
比利时贝尔塞 (美国商业资讯) — Janssen-Cilag International NV（杨森）今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)已签发一项肯定意见，推荐核准SYMTUZA™（darunavir/cobicistat/恩曲他滨/替诺福韦艾拉酚胺[D/C/F/TAF]）上市，该药是含darunavir的单一片剂方案(STR)，每天一次给药。...
View ArticleClik here to view.
ヤンセン、ダルナビルを基本とした初のHIV治療用シングルタブレットレジメンSYMTUZA™に対するCHMPの肯定的意見を取得
ベルギー・ベーアセ （ビジネスワイヤ） —...
View ArticleClik here to view.
Cogstate Receives Positive FDA Notification Regarding Medical Device...
BOSTON The cognitive science company, Cogstate today announced that its healthcare division has received notification from the U.S. Food and Drug Administration (FDA) that the Company’s 510(k)...
View ArticleClik here to view.
Dr. Reddy’s Q1 FY18 Financial Results
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE: DRREDDY) today announced its consolidated financial results for the first quarter ended June 30, 2017 under...
View ArticleClik here to view.
Dr. Reddy’s and CHD Bioscience Announce Global License and Commercialization...
FORT COLLINS, Colo. & PRINCETON, N.J. & HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and CHD Bioscience Inc., a privately-held biopharmaceutical...
View ArticleClik here to view.
苏尔寿：IDS 2017出现仿冒品和专利侵权者——苏尔寿混合技术有限公司将继续行使其权利
瑞士哈格与德国科隆 (美国商业资讯)–苏尔寿混合技术有限公司（Sulzer Mixpac Ltd，简称苏尔寿）在全球经营牙科领域的静态混合管、卡筒和胶枪。最近，公司发现了越来越多用于双组份卡筒和注射管的高仿静态混合器。这些由其他制造商生产的仿冒品并未得到SULZER严格的质量控制，因此不在公司的保修范围之内。本着客户的利益，SULZER将继续采取法律行动，打击此类仿冒行为。 Smart...
View ArticleClik here to view.
Astellas Reports First Quarter FY2017 Financial Results
TOKYO Astellas Pharma Inc. (TOKYO:4503)(President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first quarter of fiscal year 2017 (“FY2017”), ending March...
View ArticleClik here to view.
Takeda Reports 1st Quarter FY2017 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth of 6.6% led by Takeda’s Growth Drivers Underlying Revenue grew +6.6% with growth across all regions (U.S....
View ArticleClik here to view.
武田薬品: 2017年度第1四半期の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 実質的な売上収益の成長は6.6％の増収、成長ドライバーが牽引...
View ArticleClik here to view.
Accenture Develops Artificial Intelligence-Powered Solution to Help Improve...
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 BANGALORE, India Accenture (NYSE: ACN) has developed a new artificial intelligence (AI)–powered solution to help the visually impaired...
View ArticleClik here to view.
ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension...
TOKYO & VALBY, Denmark Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension was approved by the U.S....
View ArticleClik here to view.
武田公布2017财年第一季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TOKYO: 4502)： 武田增长引擎带动基础营收增长 6.6% 基础营收增长+6.6%，各地区业务均有所增长（美国+13.5%、日本 +1.6%、欧洲与加拿大 +4.6%、 新兴市场...
View ArticleClik here to view.
Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License...
INCHEON, Republic of Korea & JERUSALEM Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted...
View ArticleClik here to view.
Study Compares Performance of Masimo Acoustic Respiration Rate (RRa®) and...
TOKYO Masimo (NASDAQ: MASI) announced today that researchers at the Tokyo Women’s Medical University, Department of Anesthesiology, in Japan have published a study investigating the measurement of...
View ArticleClik here to view.
FDA计划将香烟中的尼古丁降至非成瘾性水平，22nd Century Group因此受到世人瞩目
纽约州克拉伦斯 (美国商业资讯) – 专注于烟草减害的植物生物技术公司22nd Century Group, Inc. (NYSE American:XXII)今天表示，欢迎美国食品药品管理局(FDA)的通知，即依照《家庭吸烟预防和烟草管制法案》，该局有权责令在美国销售的可燃性香烟中尼古丁含量降至非成瘾性水平。 22nd Century已能够达到FDA雄心勃勃的新产品标准。按以往报道，22nd...
View ArticleClik here to view.
Evaluate: Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017...
LONDON & BOSTON & SAN FRANCISCO & TOKYO According to life science commercial intelligence firm, Evaluate, the enforcement of a much more stringent pricing revision policy in Japan, both...
View ArticleClik here to view.
ボランティアの参加による研究でMasimo呼吸数（RRa®）とNellcorプレチスモグラフィー呼吸数の性能を比較
東京 （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、日本の東京女子医科大学麻酔科の研究者らが、ボランティアで呼吸数の測定について検討した研究の結果を公表したと発表しました。マシモのRadical-7® Pulse CO-Oximeter®を使用して測定したMasimo呼吸数（Masimo）と、Nellcor...
View ArticleClik here to view.
紙巻きたばこのニコチン含有量を中毒性のないレベルまで減らすFDAの計画は22ndセンチュリー・グループにスポットライトを当てる
米ニューヨーク州クラレンス （ビジネスワイヤ） — タバコの有害性低減に傾注する植物バイオテクノロジー企業の22ndセンチュリー・グループ（NYSE American:XXII）は本日、米食品医薬品局（FDA）が、「家庭内喫煙予防・たばこ規制法」に基づく権限を行使し、米国で販売される燃焼式紙巻きたばこのニコチンを中毒性のないレベルまで引き下げることを義務付ける計画発表を歓迎すると発表しました。...
View ArticleClik here to view.
Takeda and Cardurion Pharmaceuticals Launch Cardiovascular Development...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE: 4502) and Cardurion Pharmaceuticals today announced the creation of a new cardiovascular development partnership....
View Article